论文部分内容阅读
目的 :探索碱性成纤维细胞生长因子 ( b FGF)对视神经疾病的临床应用价值。方法 :对住院 10 8例 ( 15 9眼 )视神经疾病患者随机分为 b FGF、脑活素及对照 3个组 ,按传统常规治疗方法加用 b FGF或脑活素。以远视力作为判断疗效。结果 :b FGF组盲目复明率 ( 61.11% )明显比对照组 ( 3 2 .14 % )和脑活素组 ( 3 1.0 1% )较高 ,P均 <0 .0 5。而脑活素组与对照组间差异无显著性 ( P >0 .90 )。b FGF组总有效率 ( 66% )明显比对照组 ( 3 8.6% )和脑活素组 ( 4 4.2 3 % )高 ( P <0 .0 5 ) ,脑活素组与对照组间无显著性差异 ( P >0 .5 0 )。结论 :临床应用 b FGF治疗视神经疾病显示较好近期疗效 ,对视神经炎、视神经挫伤、外伤性及青光眼性视神经萎缩疾患有一定的治疗价值
Objective: To explore the clinical value of basic fibroblast growth factor (b FGF) in optic nerve disease. Methods: One hundred and eight patients (159 eyes) with optic neuropathy in hospital were randomly divided into bFGF, cerebrolysin and control group, and bFGF or cerebrolysin was added according to the conventional treatment. Far from the visual acuity as a curative effect. Results: The rate of blind fainting in bFGF group was significantly higher than that in control group (32.14%) and cerebrolysin group (3 1.01%) (P <0.05). There was no significant difference between cerebrolysin group and control group (P> 0.90). The total effective rate (66%) in the FGF group was significantly higher than that in the control group (36.6%) and the cerebrolysin group (4.223%) (P <0.05), and there was no significant difference between the cerebrolysin group and the control group Sex differences (P> 0.05). Conclusion: The clinical application of b FGF in the treatment of optic neuropathy shows a good short-term curative effect and has certain therapeutic value on optic neuritis, optic nerve contusion, traumatic and glaucomatous optic nerve atrophy